Palisade Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $382K | Buy |
2,742
+242
| +10% | +$33.9K | 0.01% | 279 |
|
|
2025
Q4 | $307K | Sell |
2,500
-9
| -0.4% | -$1.09K | 0.01% | 355 |
|
|
2025
Q3 | $279K | Sell |
2,509
-391
| -13% | -$44.4K | 0.01% | 361 |
|
|
2025
Q2 | $322K | Hold |
2,900
| – | – | 0.01% | 349 |
|
|
2025
Q1 | $325K | Hold |
2,900
| – | – | 0.01% | 357 |
|
|
2024
Q4 | $268K | Buy |
2,900
+300
| +12% | +$27K | 0.01% | 353 |
|
|
2024
Q3 | $218K | Buy |
+2,600
| New | +$198K | 0.01% | 358 |
|
|
2024
Q1 | – | Sell |
-3,200
| Closed | -$259K | – | 366 |
|
|
2023
Q4 | $259K | Hold |
3,200
| – | – | 0.01% | 359 |
|
|
2023
Q3 | $240K | Hold |
3,200
| – | – | 0.01% | 355 |
|
|
2023
Q2 | $247K | Hold |
3,200
| – | – | 0.01% | 352 |
|
|
2023
Q1 | $266K | Hold |
3,200
| – | – | 0.01% | 367 |
|
|
2022
Q4 | $275K | Buy |
+3,200
| New | +$253K | 0.01% | 377 |
|
|
2022
Q1 | – | Sell |
-3,200
| Closed | -$232K | – | 427 |
|
|
2021
Q4 | $232K | Sell |
3,200
-300
| -9% | -$20.7K | ﹤0.01% | 408 |
|
|
2021
Q3 | $244K | Hold |
3,500
| – | – | 0.01% | 390 |
|
|
2021
Q2 | $241K | Hold |
3,500
| – | – | 0.01% | 385 |
|
|
2021
Q1 | $226K | Hold |
3,500
| – | – | 0.01% | 368 |
|
|
2020
Q4 | $204K | Sell |
3,500
-150
| -4% | -$9.05K | 0.01% | 373 |
|
|
2020
Q3 | $231K | Hold |
3,650
| – | – | 0.01% | 374 |
|
|
2020
Q2 | $281K | Hold |
3,650
| – | – | 0.01% | 356 |
|
|
2020
Q1 | $273K | Hold |
3,650
| – | – | 0.01% | 381 |
|
|
2019
Q4 | $237K | Hold |
3,650
| – | – | 0.01% | 391 |
|
|
2019
Q3 | $231K | Hold |
3,650
| – | – | 0.01% | 402 |
|
|
2019
Q2 | $247K | Hold |
3,650
| – | – | 0.01% | 389 |
|
|
2019
Q1 | $237K | Hold |
3,650
| – | – | 0.01% | 414 |
|
|
2018
Q4 | $228K | Sell |
3,650
-4,585
| -56% | -$320K | 0.01% | 425 |
|
|
2018
Q3 | $636K | Hold |
8,235
| – | – | 0.02% | 388 |
|
|
2018
Q2 | $583K | Hold |
8,235
| – | – | 0.02% | 377 |
|
|
2018
Q1 | $621K | Sell |
8,235
-1,000
| -11% | -$79.5K | 0.02% | 371 |
|
|
2017
Q4 | $662K | Buy |
9,235
+1,000
| +12% | +$75.9K | 0.02% | 357 |
|
|
2017
Q3 | $667K | Sell |
8,235
-565
| -6% | -$43.2K | 0.02% | 353 |
|
|
2017
Q2 | $623K | Sell |
8,800
-1,500
| -15% | -$99.8K | 0.02% | 363 |
|
|
2017
Q1 | $700K | Sell |
10,300
-300
| -3% | -$21.1K | 0.03% | 342 |
|
|
2016
Q4 | $759K | Hold |
10,600
| – | – | 0.03% | 357 |
|
|
2016
Q3 | $839K | Buy |
10,600
+4,350
| +70% | +$353K | 0.03% | 434 |
|
|
2016
Q2 | $521K | Sell |
6,250
-34
| -0.5% | -$3.02K | 0.02% | 466 |
|
|
2016
Q1 | $577K | Sell |
6,284
-10,376
| -62% | -$936K | 0.02% | 457 |
|
|
2015
Q4 | $1.69M | Buy |
16,660
+160
| +1% | +$16.6K | 0.05% | 361 |
|
|
2015
Q3 | $1.62M | Buy |
16,500
+3,500
| +27% | +$389K | 0.05% | 366 |
|
|
2015
Q2 | $1.52M | Hold |
13,000
| – | – | 0.04% | 374 |
|
|
2015
Q1 | $1.28M | Buy |
13,000
+7,520
| +137% | +$764K | 0.03% | 375 |
|
|
2014
Q4 | $517K | Buy |
5,480
+500
| +10% | +$51.7K | 0.01% | 426 |
|
|
2014
Q3 | $530K | Buy |
+4,980
| New | +$488K | 0.01% | 422 |
|
Other funds holding GILD
VCM
VPM
Palisade Capital Management's GILD Position: Q1 2026 in Review
Palisade Capital Management increased its Gilead Sciences (GILD) stake by 9.7% in Q1 2026, buying an estimated $33.9K and bringing the position to 2,742 shares worth $382K. The position accounts for 0.01% of the portfolio, ranked #279.
Palisade Capital Management first reported a position in GILD in Q3 2014 and has held it in 42 quarters since. The position peaked at $1.69M in Q4 2015. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Palisade Capital Management held 2,742 shares of Gilead Sciences worth $382K as of Q1 2026.
- Palisade Capital Management bought 242 Gilead Sciences shares in Q1 2026, an estimated $33.9K.
- Gilead Sciences made up 0.01% of Palisade Capital Management's portfolio in Q1 2026, its #279 holding.
- Palisade Capital Management first reported a position in Gilead Sciences in Q3 2014 and has held it in 42 quarters since.
- Palisade Capital Management's Gilead Sciences position peaked at $1.69M in Q4 2015.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Palisade Capital Management's 13F filing for Q1 2026, filed 15 May 2026.